Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and two other insiders executed a series of transactions over a 7-day window, including open-marke | May 29, 2026 |
| EXEL | CLUSTER | neutral | 3/10 | Two EVPs at Exelixis sold a combined $3.79M in open-market sales over a week, with no insider buying. The sales are mode | May 29, 2026 |
| ETON | CLUSTER | bearish | 5/10 | Eton Pharmaceuticals CEO Sean Brynjelsen sold $3.82M worth of stock and CBO David Krempa sold $1.80M (including derivati | May 29, 2026 |
| AWHL | CLUSTER | bullish | 5/10 | Two directors at Aspira Women's Health purchased a total of $32K in shares on the same day at $0.45/share, three days af | May 29, 2026 |
| USNA | CLUSTER | neutral | 2/10 | Three USNA insiders (CFO, Chief People Officer, Director) collectively sold $250K in open-market shares over a one-week | May 29, 2026 |
| EXEL | CLUSTER | neutral | 3/10 | Two EVPs at Exelixis sold a combined $3.79M in open-market sales over a one-week window. The sales total ~0.03% of the $ | May 28, 2026 |
| NBIX | CLUSTER | neutral | 4/10 | Two Neurocrine insiders sold a combined $38.43M in shares over the past week, with Director Kevin Gorman accounting for | May 28, 2026 |
| RPRX | CLUSTER | neutral | 4/10 | Two senior executives at Royalty Pharma sold a combined $4.2M in open-market sales over a 7-day window, including the CF | May 28, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | The CEO made an open-market purchase of $864K alongside net open-market sales of ~$870K by the CEO, CFO, and General Cou | May 28, 2026 |
| OCUL | CLUSTER | neutral | 3/10 | Four OCUL insiders, including the Chief Scientific Officer and Chief Development Officer, conducted open-market sales of | May 28, 2026 |
| TWST | CLUSTER | bearish | 5/10 | A substantial insider selling cluster at Twist Bioscience, concentrated on May 21-26, 2026, with CEO Emily Leproust alon | May 28, 2026 |
| USNA | CLUSTER | neutral | 3/10 | Two USNA insiders sold $120K in shares over a 7-day window. The CFO sold $101K (5,360 shares) and a director sold $20K. | May 28, 2026 |
| AIMD | CLUSTER | neutral | 2/10 | Ainos, Inc. (AIMD) insiders executed a mixed cluster of trades over a 7-day window ending May 22, 2026. Two directors so | May 27, 2026 |
| HCWB | CLUSTER | bullish | 6/10 | Two HCWB insiders (Director Garrett and CFO Byam) made open-market purchases totaling $270K on May 22, 2026, at $1.405/s | May 27, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Two directors at BeOne Medicines sold a combined $131K in open-market transactions on May 22, 2026. The total value repr | May 27, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt made a $864K open-market purchase of 1,500 shares at $575.96 on 2026-05-26, alongside derivative e | May 27, 2026 |
| OTLK | CLUSTER | bullish | 5/10 | Two directors at Outlook Therapeutics made open-market purchases totaling ~$179K on May 26, 2026, just 13 days after the | May 27, 2026 |
| RCKT | CLUSTER | neutral | 3/10 | CEO Gaurav Shah exercised 76,490 options at $1.69 and immediately sold 55,684 shares on the open market for ~$172K, a cl | May 26, 2026 |
| SER | CLUSTER | mixed | 5/10 | Two directors at Serina Therapeutics made open-market purchases totaling $38K over a 3-day window, representing ~0.13% o | May 26, 2026 |
| KALV | CLUSTER | bearish | 5/10 | Three C-suite insiders at KalVista (CEO, CMO, CDO) sold a combined $87K in open-market sales on May 18, 2026, at $26.76/ | May 26, 2026 |
| LQDA | CLUSTER | neutral | 4/10 | CEO Roger Jeffs sold 100,000 shares (~$6.1M) over four consecutive trading days, and director/10% owner Caligan Partners | May 26, 2026 |
| PHVS | CLUSTER | neutral | 4/10 | A cluster of 8 Pharvaris insiders, including the CEO, CFO, and CCO, sold a total of $1.73M in open-market sales over a 7 | May 26, 2026 |
| BCAX | CLUSTER | neutral | 2/10 | Three top BCAX insiders (CEO, CFO, COO) sold a combined $590K in open-market shares over a 7-day window. The CFO's sale | May 26, 2026 |
| PHVS | CLUSTER | bearish | 5/10 | Six Pharvaris insiders, including the CEO, CFO, and CCO, sold a total of $1.38M in stock over a 7-day window. The cluste | May 26, 2026 |
| BBIO | CLUSTER | bearish | 5/10 | Three BridgeBio insiders, including the CEO and President/CFO, sold a total of $1.24M in open-market sales over a 7-day | May 26, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | Three top insiders at United Therapeutics (CEO, CFO, General Counsel) sold a combined ~$110K in open-market transactions | May 26, 2026 |
| ELAN | CLUSTER | neutral | 3/10 | Elanco's CEO Jeffrey Simmons and another senior executive made open-market purchases totaling $200K on May 15. In additi | May 26, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three top executives (CEO, EVP/GC, CFO) exercised stock options and sold a minimal number of shares on the open market. | May 26, 2026 |
| ELAN | CLUSTER | bullish | 4/10 | Elanco CEO Jeffrey Simmons and another insider made open-market purchases totaling $200K on May 15, 2026, at ~$20.09-$20 | May 26, 2026 |
| SER | CLUSTER | bearish | 5/10 | Two Serina directors made small open-market purchases totaling ~$38K in the 7-day window ending May 22, 2026. These trad | May 26, 2026 |